GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » Growth Rank

Argent Biopharma (ASX:RGT) Growth Rank : 4 (As of Jun. 04, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Argent Biopharma Growth Rank?

Argent Biopharma has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Competitive Comparison of Argent Biopharma's Growth Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argent Biopharma's Growth Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Growth Rank distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Growth Rank falls into.



Argent Biopharma Growth Rank Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma (ASX:RGT) Business Description

Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardized, affordable plant-derived medicines of the highest regulatory compliance for targeted global markets.

Argent Biopharma (ASX:RGT) Headlines

From GuruFocus

Royce Global Value Trust (NYSE: RGT) as of Apr 30, 2022

By PRNewswire PRNewswire 07-03-2022

Royce Global Value Trust (NYSE: RGT) as of Apr 30, 2022

By PRNewswire PRNewswire 06-03-2022

Royce Global Value Trust (NYSE: RGT) as of Mar 31, 2023

By PRNewswire PRNewswire 04-26-2023

Royce Global Value Trust (NYSE: RGT) as of Jan 31, 2022

By PRNewswire PRNewswire 02-23-2022

Royce Global Value Trust (NYSE: RGT) as of Apr 30, 2023

By PRNewswire PRNewswire 05-25-2023

Royce Global Value Trust (NYSE: RGT) as of Sep 30, 2022

By PRNewswire PRNewswire 10-28-2022

Royce Global Value Trust (NYSE: RGT) as of Jan 31, 2023

By PRNewswire PRNewswire 02-27-2023

Royce Global Value Trust (NYSE: RGT) as of May 31, 2022

By PRNewswire PRNewswire 07-08-2022

Royce Global Value Trust (NYSE: RGT) as of Jun 30, 2022

By PRNewswire PRNewswire 07-29-2022